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Results of investigations on the development of new regulators of functional activity of nucleic acid biosynthesis
enzymes based on polycyclic nitrogen-containing heterosystems are summarized. Computer design and molecu-
lar docking in the catalytic site of target enzyme (T7pol) allowed to perform the directed optimization of basic
structures. Several series of compounds were obtained and efficient inhibitors of herpes family (simple herpes vi-
rus type 2, Epstein-Barr virus), influenza A and hepatitis C viruses were identified, as well as compounds with po-
tent antitumor, antibacterial and antifungal activity. It was established that the use of model test systems based
on enzymes participating in nucleic acids synthesis is a promising approach to the primary screening of poten-
tial inhibitors in vitro.
Keywords: 6-azacytidine, as-triazinic nucleosides, acridones, phenazines, benzimidazothiazolones, inhibitors.
The Department of Synthetic Bioregulators (initially
headed by A. D. Shved, PhD, and since 2009 – by I. Ya.
Dubey) was established in 1998 via integration of two
laboratories of IMBG to consolidate the scientific efforts
of specialists in the fields of chemistry and biology,
directed at elaborating synthetic inhibitors and using
them in molecular and biological, biochemical and me-
dical investigations.
The initial stage of the department work was logical
continuation of previous scientific investigations on the
chemical synthesis of antiviral and antitumor prepara-
tions on the basis of antisense-ribozyme approach to the
control and inhibition of viral infections. By that time
about 200 derivatives of triazine bases, N-glycosides,
differing in sugar content, and hybrid compounds (Fi-
gure, structures 1–3) were synthesized and studied.
The research work «Elaboration of a new antiviral
and anti-mycoplasmal preparation on the basis of sub-
stance 6-azacytidine» (1997–2000) was successfully
performed due to creative collaboration with laborato-
ries of several institutes of NAS and NAMS of Ukraine.
300 gram of 6-azacytidine were obtained in IMBGwith
experimental facilities by the elaborated technology.We
carried out toxic-pharmacological investigations of the
synthesized preparation, elaborated analytical and nor-
mative documents for the substance and pharmaceuti-
cal form as well as the pilot manufacturing instructions
for the substance production and technological instruc-
tion for obtaining sterile injectable preparation of 6-aza-
cytidine (6-ÀÑ, 1).
The independent testing on virus-cell models and la-
boratory animals allowed determining significant inhi-
bitory activity of the substance and the elaborated injec-
table pharmaceutical form of 6-azacytidine against ade-
noviral, herpetic and mycoplasmal infections [1–5].
For instance, Zarubayev et al. (Research Institute of In-
fluenza, RAMS) discovered a therapeutic effect of the
preparation during experimental systemic adenoviral in-
fection of newborn hamsters [2]. In 2011 the same au-
thors demonstrated that compared to the novel Russian
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preparation Ingavirin, the antiviral activity of 6-azacyti-
dine in experiments with animals was higher by a factor
of ten [3].
The laboratory testing of the pharmaceutical form
6-AC, performed by Prof. S. L. Rybalko in the L. V.
Gromashevsky Institute of Epidemiology and Infectious
Diseases, using the model of herpetic meningoence-
phalitis in mice, demonstrated reliable and highly effi-
cient curative and prophylactic effect of the preparation
and its low toxicity [4, 5]. Besides, the antimycoplas-
mal effect of the preparation was proven on the model
of bronchopneumonia of mice while infecting Ìyco-
plasma hominis (A. V. Rudenko, Urology Institute of
NAMS of Ukraine), the ability of 6-azacytidine to in-
duce the synthesis of interferon and to stimulate the
functional activity of T- and B-lymphocytes was revea-
led in vitro and in vivo experiments [6].
Taking into account the absence of a licensed anti-
adenoviral preparations on the worldmarket, the data re-
ceived testify to the feasibility of further clinical trials
of 6-azacytidine as a potential medical preparation.
In 2001 the Department of Synthetic Bioregulators
developed and patented the new approach to the synthe-
sis of triazine nucleosides on the basis of the simplified
one-pot version of «silyl condensation» method. The
suggested convenient approach secured a high yield of
target products, and ensured the possibility of obtaining
both 6-azacytidine and its different derivatives and N-
glycoside analogues, following the simplified scheme of
nucleoside synthesis [7, 8].
A more complex approach was used for the synthe-
sis of dideoxyderivatives of 6-azacytidine i. e. the trans-
formation of yielded ribonucleoside using chemical
methods with haloid-containing phosphonium reagent;
also the mechanism of consecutive transformation of
initial compounds into corresponding deoxyderivati-
ves was determined. We established that during deoxy-
genation of 5'-Î-benzoyl-6-azacytidine the intermedia-
te compound is 2',3'-epoxy-derivative of 6-azacytidine
instead of 2',Î2-cyclonucleoside, as observed in the re-
action with pyrimidine nucleosides. The following de-
velopment of the epoxide cycle under the impact of the
abovementioned reagents resulted in the formation of
2',3'-dihaloid-2',3'-dideoxy-6-azacytidine or nucleosi-
de analogue with non-saturated bond in the carbohyd-
rate fragment – 2',3'-didehydro-2',3'-dideoxy-6-azacy-
tidine [9].
Further search for more active anti-adenoviral com-
pounds among synthesized analogues and derivatives of
6-AC was performed by analyzing the structure-activity
relationship of these compounds. The Quantitative
Structure-Activity Relationship (QSAR) method was
used to determine separate molecular fragments, enhan-
cing the antiadenoviral activity [10]. High activity of 6-
azacytidine analogues, determined by QSAR method,
correlates rather efficiently with that, experimentally ob-
tained for new compounds: 2'-deoxy-, 2',3'-dideoxy- and
2',3'-epoxy-derivatives of 6-ÀÑ, its acyclic and xylofu-
ranose analogues [8, 11, 12].
The PM3 method was used to perform semi-empi-
rical quantum-chemical calculations of 6-ÀÑ, while
the àb initiomethod was applied for non-empirical cal-
culations on the level of theory ÌÐ2 6-311++G(3df,
3pd) // MP2-6-311++G(d,p). We determined five most
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beneficial energy-wise structures of azanucleoside with
different conformations of ribose fragment and orienta-
tion of heterocyclic base in the range of relative ener-
gies of 0–3.7 kcal/mol [13]. In our opinion, the location
of 6-ÀÑ in syn-conformation results in a steric hind-
rance to its metabolic transformations (for instance, 5'-
Î-phosphorylation), which are the basis of the effect of
modified nucleosides. However, as proven by the obtai-
ned results, each selected 6-AC conformation may be
the candidate for biologically active «working» con-
formation depending on the target.
The capability of 1,2,4-triazine derivatives to play
the role of «universal base», capable of forming strong
complexes with canonic Thy, Ade, Cyt, Gua, prompted
us to perform triazine-based synthesis of the hybrid
compounds with phenazine-1-carboxylic acid (PCA-1;
2) – non-nucleoside inhibitors [14]. At the same time,
taking into account pharmacophoric properties of car-
boxamide group, we developed convenient methods of
obtaining the series of N-substituted amides of triazi-
nyl-6-propanecarboxylic acid (PCA; 3) [15, 16] and
N-arylamides of PCA-1 (4) [17].
The system simulating the transcription, based on
DNA-dependent RNA-polymerase of bacteriophage T7
(T7pol), was adapted for accelerated testing new com-
pounds for biological activity [15–19]. The advantages
of this model are its availability, synthesis productivity,
plain quantitative determination of results, the possibi-
lity of simultaneous testing of dozens of substances in
different variants of experiments and estimation of the
affinity of compounds to DNA-matrix, the enzyme or
to the transcriptional complex. Following the results of
testing in the transcription system in vitrowe revealed a
number of carboxamides, inhibiting RNA synthesis at
the concentration of 25 µg/ml.
The application of this system allowed extending
the library of compounds of this chemotype at the
expense of N-hetarylamides PCA- 1 and 9-methyl-
PCA-1 and N-arylamides of acridone- 4-carboxylic
acid (ACA-4; 5). After the screening in T7 pol system
the samples of compounds – efficient transcription
inhibitors – were investigated for the antibacterial, anti-
fungal, antituberculosis and antiviral activity. Among
three dozens of investigated PCA amides there were
three compounds, the antifungal activity of which
regarding the strains of Ñandida albicans was higher
than that of the well-known medical preparation diflu-
can (fluconazole) [15].
21 compounds from the series of N-arylamides of
PCA-1 demonstrated antituberculosis activity regarding
the wild strainMycobacterium tuberculosis with mini-
mal inhibitory concentration (MIC) in the range of 0.5–
2.7 µM, i. e. at the level of the effect of isoniazid and
rifampicin (MIC of 1.4 and 0.95 µM, respectively).
Here some compounds were active against clinical iso-
lates of Ì. tuberculosis with multiple resistance [17].
Considerable antibacterial activity regarding both gram-
positive and gram-negative bacteria was demonstrated
by arylamides of both 9-substituted and non-substitu-
ted PCA-1 [18].
A series of 27 N-arylamides of ACA-4 were studi-
ed in the testing of enzymatic systems of hepatitis C vi-
rus (HCV) replication in vitro on the basis of NS3-heli-
case of the virus and subgenome replicon of HCV. Five
compounds demonstrated their ability of efficient (ÅÑ50
5.6–11.1 µM) inhibition of helicase complex of HCV
RNA-genome [19].
The department performed a considerable cycle of
works [20–23] on the synthesis and investigation of de-
rivatives of 3-oxo-1,2,4-triazine[5,6-b][1,4]benzothia-
zine (3-oxo-1,2,4-TBT; 6) – the structural analogues of
triazine-containing polycyclic antibiotics. In part we
changed the procedure of searching for potential inhibi-
tors of T7pol using the molecular docking method and
started computational investigation in determining the
topology and tautomeric status of themain compound –
3-oxo-1,2,4-TBT. It was established that the structure
of only one out of three most probable tautomers was
close to the planar one, and it was themost advantegous
energy-wise. According to the spectral data, this tauto-
mer is formed during the synthesis, thus, it was used for
docking to study the interaction of the investigated class
of compounds with the T7pol active site.
The key non-covalent intermolecular relations of di-
fferent types were determined for the ligand-receptor co-
mplex. The experimental data regarding the biological
activity of the synthesized compounds are in sufficient
agreement with the results of virtual screening [21].
Two methods of obtaining tricyclic analogues of
nucleosides with triazine fragment were elaborated. The
triazine-containing tricyclic bases were modified by di-
rect glycosylation of peracyl-derivative of sugar in con-
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ditions of the simplified version of «silyl condensa-
tion» method. Another way is the formation of tricyclic
heterobase with fixed location of the sugar residue, ta-
king into account corresponding triazine nucleosides,
where the heterocycle is finished completely. This was
the way to confirm the region-specificity of the glycosy-
lation reaction as well as to reveal the dependence of the
synthesis efficiency on the nature of benzene ring sub-
stitutes (method 1) or the substitutes of ortho-amino-
thiophenol – the initial compound in the annelation
reaction (method 2) [20–21].
There was the in vitro investigation of the activity of
tricyclic bases and their glycosides in the enzymatic test-
systems and the impact of compounds on the reproduc-
tion of viruses ofHerpes viridae family – herpex simp-
lex virus, type 2 (HSV-2) and Epstein-Barr virus (EBV)
(Table) [22, 23].
The investigation of triazine-benzothiazines in cell
cultures, infected with herpes-viruses (HSV-2 and
EBV), demonstrated that all substances are capable of
efficient inhibition of the reproduction of both viruses
with ÅÑ50 in the range of 2.7–15.9 µM. Here the antivi-
ral properties of glycoside derivatives of tricyclic bases
(N2-ribofuranosides) were stronger that the properties
of the bases [20]. Taking into consideration that TBT
derivatives are also inhibitors of transcription and re-
plication of DNA in vitro, one can assume that the me-
chanism of antiviral activity of the compounds may be
based on inhibiting the functioning of transcriptional
and replicative complexes.
All the previously considered condensed hetero-
cyclic compounds are built on the basis of linear tricyc-
lic systems (phenazine, acridine, triazine-benzothiazi-
ne). However, the obtaining and investigation of com-
pounds with other molecular structures were of interest
as well. The inhibitors, active regarding the enzymes of
the system of nucleic acid biosynthesis, are known to
contain specific «banana»- or S-like polycyclic structu-
ral fragments.
Based on this fact, we obtained about 30 arylidene
derivatives of [1,3]tiazole[3,2-a]benzimidazole-3 (2H)-
one(benzimidazothiazolone) – BT series compounds
(7). The convenient method of synthesizing such sub-
stances was developed on the basis of the condensation
of aromatic aldehydes with benzimidazothiazolone in
the sodium acetate – acetic acid system.
It is noteworthy that despite the general structure of
arylidene BT derivatives was confirmed by NMR and
mass spectrometry, there was no unified view on the
spatial configuration of molecules of these compounds.
The quantum-chemical calculations of the transitory
state of the reaction of forming BT compoundswere used
to demonstrate that cys-isomer should be realized in all
cases. The X-ray structural analysis of BT derivatives
confirmed their cys-configuration regarding the double
bond in arylidene fragment of the molecule.
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Compound
Transcription test-systems
T7pol, ²Ñ90, µM
PCR test-systems,
²Ñ90, µM
HSV-2 ( ÂÍ) in cell culture
RÊ-13, ÅÑ50, µM
EBV in cell culture Raji,
ÅÑ50, µM
3-oxo-TBT 100 >100 2,7 4,6
3-oxo-TBT (Rib) 85,7 57,0 3,14 2,7
3-oxo-TBT (Rib) 89,0 N 4,5 2,8
3-oxo-TBT (7-Ñl) 99,0 99,0 12,5 N
3-oxo-TBT (8-Âu) 22,5 75,0 15,9 N
3-oxo-TBT (7-ÑF3) 87,4 87,0 7,0 N
3-oxo-TBT (Rib, 7-CF3) 71,7 47,8 3,9 N
N o t e. 3-oxo-TBT (core base) – 3-oxo-1,2,4-triazine[5,6-b][1,4]benzothiazine; Rib – N2-ribofuranoside; N – don’t investigated.
Inhibitory properties of triazine-benzothiazine derivatives (TBT) in enzymatic and viral-cellular model systems
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BT derivatives demonstrated the highest inhibitory
activity among the investigated compounds in the test-
system of in vitro transcription. The level of activity
depends on the nature of the substitute in the arylidene
fragment. For three substances the value of ²Ñ50 in the
T7pol system is close to 10 µM, while for BT-29 sub-
stance, containing a dihydroxyphenyl fragment, it is
1.6 µM. In the concentration of 0.7 µg/ml (2 µM), this
inhibitor ensures almost absolute inhibition of RNA
synthesis. At the same time, the investigation of the im-
pact of BT series compounds on the activity of topoiso-
merase ² of Escherichia coli in the system of DNA re-
laxation in vitro did not reveal their inhibitory effect in
the concentration of 50–100 µM.
The biological investigations of benzimidazole using
the models of pathogenic bacterial (gram-positive –
aurococcus Staphylococcus aureus, gram-negative –
blue pus bacillus Pseudomonas aeruginosa) and fungal
(C. albicans) infections did not reveal any compounds
with the antimicrobial or antifungal activity. However,
the significant anti-herpetic activity was revealed in the
virus–cell system (the culture of continuous BHK
cells) for a number of BT derivatives with a hydroxyl-
or dimethylaminogroup in the phenyl nucleus. The
MIC value for four compounds was in the range of
1.6–3.6 µM, and the selectivity index – in the range of
90–250. At the same time some derivatives of BT series
with OH- and Et2N-substitutes in the arylidene frag-
ment, remarkable for the highest inhibitory activity in
the transcription system, demonstrated a significant an-
tiproliferative activity in vitro in the cultures of tumor
HeLa cells (EC50 1.1–2.9 µM) andMCF-7 (human breast
carcinoma, ÅÑ50 0.9–1.6 µM).
Conclusions. Since the very establishment of the
Department of Synthetic Bioregulators the main focus
area has been the elaboration of new approaches to the
creation of polynucleate nitrogen-containing systems –
regulators of functional activity of the enzymes, main-
taining the biosynthesis of nucleic acids. The quantum-
chemical calculations, computational simulation of the
structures of ligands and their complexes with targets
allowed modeling several series of biologically active
compounds on the basis of condensed 1,2,4-triazine,
N-substituted amides of triazinyl-6-propane carboxylic
acid, N-arylamides of phenazine-1-carboxylic acids, N-
hetarylamides of acridone-4-carboxylic acid and arylide-
ne-substituted benzimidazothiazolones. The simulated
test-systems of transcription, and, partially, replication
and relaxation of DNA were used for initial screening
the synthesized compounds in vitro. The selection of
these systems seems to be reasonable, because themen-
tioned biological processes are the principal targets of
antimicrobial, antiviral and antitumor therapy. A targe-
ted selection of new substances with subsequent investi-
gation on the cellular level allowed revealing at least 3–
4 leader compounds in each obtained series, which are
promising for further study and structural optimization.
The abovementioned results of investigations were
used for three PhD theses, 50 publications, 5 patents and
numerous reports at national and international scientific
forums.
². Â. Àëåêñººâà, À. Ä. Øâåä
Ñèíòåç ³ äîñë³äæåííÿ á³îëîã³÷íî¿ àêòèâíîñò³ àçîòîâì³ñíèõ
ãåòåðîöèêë³÷íèõ ñïîëóê – ðåãóëÿòîð³â ôåðìåíò³â á³îñèíòåçó
íóêëå¿íîâèõ êèñëîò
Ðåçþìå
Óçàãàëüíåíî ðåçóëüòàòè äîñë³äæåíü ùîäî ñòâîðåííÿ íîâèõ ðåãó-
ëÿòîð³â ôóíêö³îíàëüíî¿ àêòèâíîñò³ ôåðìåíò³â á³îñèíòåçó íóê-
ëå¿íîâèõ êèñëîò íà îñíîâ³ ïîë³öèêë³÷íèõ àçîòîâì³ñíèõ ãåòåðîñè-
ñòåì. Êîìï’þòåðíèé äèçàéí ³ ìîëåêóëÿðíèé äîê³íã ó êàòàë³òè÷-
íèé ñàéò ôåðìåíòó-ì³øåí³ (Ò7ïîë) äîçâîëèëè ïðîâåñòè ñïðÿìî-
âàíó îïòèì³çàö³þ áàçîâèõ ñòðóêòóð. Îòðèìàíî äåê³ëüêà ñåð³é ñïî-
ëóê, ç-ïîì³æ ÿêèõ âèÿâëåíî åôåêòèâí³ ³íã³á³òîðè â³ðóñ³â ðîäèíè
ãåðïåñó (ÂÏÃ-2, â³ðóñ Åïøòåéíà-Áàðð), ãðèïó À òà ãåïàòèòó Ñ, à
òàêîæ ïðåïàðàòè ç ïîòóæíîþ ïðîòèïóõëèííîþ, ïðîòèáàêòå-
ð³éíîþ òà ïðîòèôóíãàëüíîþ ä³ºþ. Âèçíà÷åíî ïåðñïåêòèâí³ñòü
çàñòîñóâàííÿ ìîäåëüíèõ òåñò-ñèñòåì íà îñíîâ³ ôåðìåíò³â, ùî
îáñëóãîâóþòü ñèíòåç íóêëå¿íîâèõ êèñëîò, äëÿ ïåðâèííîãî ñêðèí³í-
ãó ïîòåíö³éíèõ ³íã³á³òîð³â in vitro.
Êëþ÷îâ³ ñëîâà: 6-àçàöèòèäèí, íóêëåîçèäè as-òðèàçèíà, àêðè-
äîíè, ôåíàçèíè, áåíç³ì³äàçîò³àçîëîíè, ³íã³á³òîðè.
È. Â. Àëåêñååâà, À. Ä. Øâåä
Ñèíòåç è èçó÷åíèå áèîëîãè÷åñêîé àêòèâíîñòè
àçîòñîäåðæàùèõ ãåòåðîöèêëè÷åñêèõ ñîåäèíåíèé –
ðåãóëÿòîðîâ ôåðìåíòîâ áèîñèíòåçà íóêëåèíîâûõ êèñëîò
Ðåçþìå
Îáîáùåíû ðåçóëüòàòû èññëåäîâàíèé ïî ñîçäàíèþ íîâûõ ðåãóëÿ-
òîðîâ ôóíêöèîíàëüíîé àêòèâíîñòè ôåðìåíòîâ áèîñèíòåçà íóê-
ëåèíîâûõ êèñëîò íà îñíîâå ïîëèöèêëè÷åñêèõ àçîòîñîäåðæàùèõ
ãåòåðîñèñòåì. Êîìïüþòåðíûé äèçàéí è ìîëåêóëÿðíûé äîêèíã â
êàòàëèè÷åñêèé ñàéò ôåðìåíòà-ìèøåíè (Ò7ïîë) ïîçâîëèëè ïðîâå-
ñòè íàïðàâëåííóþ îïòèìèçàöèþ áàçîâûõ ñòðóêòóð. Ïîëó÷åíî íå-
ñêîëüêî ñåðèé ñîåäèíåíèé, ñðåäè êîòîðûõ âûÿâëåíû ýôôåêòèâ-
íûå èíãèáèòîðû âèðóñîâ ñåìåéñòâà ãåðïåñà (ÂÏÃ-2, âèðóñ Ýïø-
òåéíà-Áàðð), ãðèïïà À è ãåïàòèòà Ñ, à òàêæå ïðåïàðàòû ñ ìîù-
íûì ïðîòèâîîïóõîëåâûì, àíòèáàêòåðèàëüíûì è àíòèôóíãàëü-
íûì äåéñòâèåì. Îïðåäåëåíà ïåðñïåêòèâíîñòü ïðèìåíåíèÿ ìî-
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äåëüíûõ òåñò-ñèñòåì íà îñíîâå ôåðìåíòîâ, îáñëóæèâàþùèõ ñèí-
òåç íóêëåèíîâûõ êèñëîò, äëÿ ïåðâè÷íîãî ñêðèíèíãà ïîòåíöèàëü-
íûõ èíãèáèòîðîâ in vitro.
Êëþ÷åâûå ñëîâà: 6-àçàöèòèäèí, íóêëåîçèäû as-òðèàçèíà, àê-
ðèäîíû, ôåíåçèíû, áåíçèìèäàçîòèàçîëîíû, èíãèáèòîðû.
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